DOP2023000119A - Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma - Google Patents

Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma

Info

Publication number
DOP2023000119A
DOP2023000119A DO2023000119A DO2023000119A DOP2023000119A DO P2023000119 A DOP2023000119 A DO P2023000119A DO 2023000119 A DO2023000119 A DO 2023000119A DO 2023000119 A DO2023000119 A DO 2023000119A DO P2023000119 A DOP2023000119 A DO P2023000119A
Authority
DO
Dominican Republic
Prior art keywords
indazol
carboxamide
formula
cyclohexyl
pyridazin
Prior art date
Application number
DO2023000119A
Other languages
English (en)
Inventor
Terstiege Ina
Schiesser Stefan
Xue Yafeng
Chang Hui-Fang
Ingrid Kristina Berggren Anna
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2023000119A publication Critical patent/DOP2023000119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a un compuesto de Fórmula (A), en donde R1 se selecciona entre la Fórmula (II) y Fórmula (III) y R2 se selecciona entre la Fórmula (IV), Fórmula (V) y Fórmula (VI) como inhibidores de IRAK4 para su uso en métodos de tratamiento de, por ejemplo, asma y enfermedad pulmonar obstructiva crónica (EPOC), cáncer, enfermedades inflamatorias y enfermedades autoinflamatorias/autoinmunitarias tales como, por ejemplo, el lupus eritematoso sistémico, artritis reumatoide, miositis, síndrome de Sjögren, esclerosis sistémica, gota, endometriosis, dermatitis atópica y psoriasis. Los compuestos preferidos de la presente invención son, por ejemplo: derivados de ¿ N-(imidazo[1,2-b]piridazin-3-il)-1-ciclohexil-2H-indazol-5-carboxamida, ¿ N-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2H-indazol-5-carboxamida, ¿ N-(imidazo[1,2-b]piridazin-3-il)-1-azaespiro[4.5]decan-8-il-2H-indazol-5-carboxamida y ¿ N-(pirazolo[1,5-a]pirimidin-3-il)-1-azaespiro[4.5]decan-8-il-2H-indazol-5-carboxamida. Un compuesto de ejemplo de la presente invención es, por ejemplo, N-(imidazo[1,2-b]piridazin-3-il)-6-metoxi-2-((5r,8r)-1-metil-2-oxo-1-azaespiro[4.5]decan-8-il)-2H-indazol-5-carboxamida (Ejemplo 1): Fórmula (VII).
DO2023000119A 2020-12-10 2023-06-09 Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma DOP2023000119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063199160P 2020-12-10 2020-12-10
PCT/EP2021/084916 WO2022122876A1 (en) 2020-12-10 2021-12-09 N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma

Publications (1)

Publication Number Publication Date
DOP2023000119A true DOP2023000119A (es) 2023-07-09

Family

ID=79230946

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000119A DOP2023000119A (es) 2020-12-10 2023-06-09 Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma

Country Status (20)

Country Link
US (1) US11866405B2 (es)
EP (1) EP4259632A1 (es)
JP (1) JP2023552838A (es)
KR (1) KR20230118153A (es)
CN (1) CN116583285A (es)
AR (1) AR124303A1 (es)
AU (1) AU2021395816B2 (es)
CA (1) CA3203569A1 (es)
CL (1) CL2023001662A1 (es)
CO (1) CO2023007624A2 (es)
CR (1) CR20230264A (es)
DO (1) DOP2023000119A (es)
EC (1) ECSP23050553A (es)
IL (1) IL303356A (es)
MX (1) MX2023006816A (es)
PE (1) PE20240684A1 (es)
TW (1) TW202237612A (es)
UY (1) UY39561A (es)
WO (1) WO2022122876A1 (es)
ZA (1) ZA202306848B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152349A1 (en) * 2022-02-14 2023-08-17 Astrazeneca Ab Irak4 inhibitors
WO2023227703A1 (en) * 2022-05-26 2023-11-30 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2604062C2 (ru) 2010-07-13 2016-12-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
US9073892B2 (en) 2010-12-20 2015-07-07 Merck Serono S.A. Indazolyl triazol derivatives
CA2903490C (en) 2013-03-15 2021-04-13 Biomarin Pharmaceutical Inc. Hdac inhibitors
SG11201605408RA (en) 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
EA032559B1 (ru) 2014-04-04 2019-06-28 Пфайзер Инк. Бициклические аннелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
AU2016293446A1 (en) 2015-07-15 2018-02-15 Aurigene Discovery Technologies Limited Substituted aza compounds as IRAK-4 inhibitors
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
CA3016364A1 (en) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
BR112018074919A2 (pt) 2016-06-01 2020-11-03 Bayer Pharma Aktiengesellschaft uso de indazóis 2-substituídos para tratamento e profilaxia de doenças autoimunes.
CN110770229A (zh) 2017-06-21 2020-02-07 豪夫迈·罗氏有限公司 作为irak4调节剂的苯并呋喃化合物
EP3642201A1 (en) 2017-06-21 2020-04-29 H. Hoffnabb-La Roche Ag Isoindolinone derivatives as irak4 modulators
EP3990454A1 (en) 2019-06-27 2022-05-04 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease
BR112021026369A2 (pt) 2019-06-27 2022-05-17 Biogen Ma Inc Derivados de 2h-indazol e seu uso no tratamento de doenças

Also Published As

Publication number Publication date
EP4259632A1 (en) 2023-10-18
IL303356A (en) 2023-08-01
JP2023552838A (ja) 2023-12-19
US11866405B2 (en) 2024-01-09
US20220185817A1 (en) 2022-06-16
AU2021395816B2 (en) 2024-04-04
CN116583285A (zh) 2023-08-11
UY39561A (es) 2022-06-30
MX2023006816A (es) 2023-06-21
WO2022122876A1 (en) 2022-06-16
ECSP23050553A (es) 2023-08-31
PE20240684A1 (es) 2024-04-10
AR124303A1 (es) 2023-03-15
CL2023001662A1 (es) 2024-01-12
ZA202306848B (en) 2024-04-24
CA3203569A1 (en) 2022-06-16
AU2021395816A1 (en) 2023-07-13
CO2023007624A2 (es) 2023-06-30
CR20230264A (es) 2023-07-26
TW202237612A (zh) 2022-10-01
KR20230118153A (ko) 2023-08-10

Similar Documents

Publication Publication Date Title
DOP2023000119A (es) Derivados de n-(imidazo)[1,2-b]piridazin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida y de n-(pirazolo[1,5-a]pirimidin-3-il)-1-ciclohexil-2h-indazol-5-carboxamida como inhibidores de irak4 para el tratamiento del asma
PE20211001A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
JP6298114B2 (ja) 新規な三環式化合物
TWI741423B (zh) 雜芳類衍生物調節劑、其製備方法和應用
JP2017503867A5 (es)
US11919902B2 (en) Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
RU2014115478A (ru) Новые гетероциклические производные и их применения
JP2014531458A5 (es)
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
MX2013003913A (es) Compuestos de furo [3, 2-d] pirimidina.
WO2013043826A1 (en) Tricyclic compounds useful as protein kinase inhibitors
WO2009152133A1 (en) Novel tricyclic compounds
JP6467404B2 (ja) Ｐ２ｘ７モジュレーター
WO2012149280A2 (en) Novel tricyclic compounds
SG181147A1 (en) Novel tricyclic compounds
CA2620223A1 (en) Novel imidazo based heterocycles
KR20120047924A (ko) Ｐｉ3ｋ 저해물질로서의 피리미디논
JP2016504363A5 (es)
EP2170337A1 (en) Novel triazolopyridazines
JP2014530172A (ja) ピロロピラジンキナーゼ阻害剤
JP2011513261A (ja) ピロロピラジンキナーゼ阻害剤
EP3697784B9 (en) Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2021032582A1 (en) Pyrazolo[4,3-c]pyridine derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Dyachenko et al. Fused pyrimidine systems: XIII. Synthesis and some transformations of 1, 3-thiazolo (thiazino)-fused pyrido [3, 4-d] pyrimidines
CN112867715B (zh) 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物